KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Payables: 2017-2024

Historic Payables for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $10.3 million.

  • Aquestive Therapeutics' Payables rose 43.49% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 38.71%. This contributed to the annual value of $10.3 million for FY2024, which is 15.25% up from last year.
  • As of FY2024, Aquestive Therapeutics' Payables stood at $10.3 million, which was up 15.25% from $8.9 million recorded in FY2023.
  • Aquestive Therapeutics' Payables' 5-year high stood at $10.3 million during FY2024, with a 5-year trough of $7.1 million in FY2020.
  • In the last 3 years, Aquestive Therapeutics' Payables had a median value of $9.9 million in 2022 and averaged $9.7 million.
  • In the last 5 years, Aquestive Therapeutics' Payables slumped by 42.24% in 2020 and then increased by 19.63% in 2022.
  • Aquestive Therapeutics' Payables (Yearly) stood at $7.1 million in 2020, then grew by 17.28% to $8.3 million in 2021, then grew by 19.63% to $9.9 million in 2022, then dropped by 10.26% to $8.9 million in 2023, then rose by 15.25% to $10.3 million in 2024.